TYK2 Inhibitor Selectivity via JH2 Domain Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK inhibitors lack selectivity, leading to adverse reactions due to their action on multiple JAK family kinases, particularly TYK2, which is involved in inflammatory and immune response pathways.
Innovation Solution
A substituted pyridazine-3-carboxamide compound that selectively inhibits TYK2 by binding to its pseudokinase domain (JH2), offering a therapeutic approach to treat TYK2-mediated diseases with reduced adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If common small molecule JAK inhibitors are used to inhibit JAK family kinases, then broad inhibition of JAK-mediated signaling pathways is achieved, but selectivity is low leading to adverse reactions
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features that selectively interact with unique residues in the TYK2 JH2 domain. The compounds incorporate specific substituent patterns (R1, R2, R3 groups) that create localized interactions with TYK2-specific amino acid sequences, enabling selective inhibition of TYK2 while sparing other JAK family members.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the pyridazine-3-carboxamide core structure, including substituent types, positions, and configurations. By optimizing parameters such as the nature of R1 (haloalkyl, alkyl), R2 (cycloalkyl, aryl), and R3 (alkyl) groups, the invention achieves enhanced selectivity for TYK2 over other JAK kinases while maintaining potent inhibition.
2Reliability
If ATP site-directed inhibitors are used against JAK proteins, then catalytic activity is inhibited, but selectivity among JAK family members is compromised due to high homology of ATP sites
Solution Approach 1:
The patent extracts the inhibitory action from the conserved ATP-binding site to the more divergent pseudokinase JH2 domain. By designing compounds that specifically target the JH2 domain rather than the catalytic ATP site, the invention exploits structural differences in the JH2 region among JAK family members to achieve selective inhibition of TYK2 while avoiding off-target effects on other kinases.
Solution Approach 2:
The patent uses the pseudokinase JH2 domain as an intermediary target between the ATP site and the catalytic domain. The JH2 domain acts as a regulatory element that, when inhibited, allosterically affects the catalytic activity of TYK2. This intermediary approach allows for selective modulation of TYK2 function through its unique JH2 structure without directly competing at the highly conserved ATP site.
Data Source
AI summary
The present invention provides a pyridazine-3-carboxamide compound represented by general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof. The present invention further provides a pharmaceutical composition including the compound, a preparation method therefor and a use thereof in treating or preventing a TYK2 kinase-mediated disease.